Nemaura Medical to Present at the Benzinga Healthcare Small Cap Conference

Rhea-AI Summary

Nemaura Medical (NASDAQ: NMRD) announces that its CEO, Faz Chowdhury, Ph.D., will present at the Benzinga Healthcare Small Cap Conference on September 29 at 11:10 AM ET. The event will be held virtually from September 29-30, 2021, with Dr. Chowdhury available for one-on-one meetings during the conference. Nemaura focuses on non-invasive wearable diagnostic technology and is currently commercializing products like sugarBEAT® and proBEAT™, which aim to improve diabetes management.

Loughborough, England, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 – 30, 2021.

Dr. Chowdhury will deliver his corporate presentation on September 29 at 11:10 AM ET.

Dr. Chowdhury will also be available for one-on-one meetings throughout the conference

Investors can register for the conference here: https://www.benzinga.com/events/small-cap/healthcare/

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

When is Nemaura Medical's CEO presenting at the Benzinga Conference?

Nemaura Medical's CEO, Faz Chowdhury, will present on September 29, 2021, at 11:10 AM ET.

What products is Nemaura Medical known for?

Nemaura Medical is known for its non-invasive wearable diagnostic devices, including sugarBEAT® and proBEAT™.

Where can I register for the Benzinga Healthcare Small Cap Conference?

You can register for the Benzinga Healthcare Small Cap Conference at https://www.benzinga.com/events/small-cap/healthcare/.

Is sugarBEAT® approved for use?

Yes, sugarBEAT® is a CE mark approved Class IIb medical device.

What market does Nemaura Medical operate in?

Nemaura Medical operates in the global Type 2 diabetes market, estimated to reach $59 billion by 2025.